PharmaShots | Incisive News in 3 Shots

Subscribe Now

higher-risk myelodysplastic syndromes

Takeda's Pevonedistat Receives the US FDA's Breakthrough Therapy Designation to Treat Patients with Higher-Risk Myelodysplastic Syndrome

Takeda's Pevonedistat Receives the US FDA's Breakthrough Therapy Designation to Treat Patients with Higher-Risk Myelodysplastic Sy...

July 31, 2020

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us